HTR6 Gene — 5-Hydroxytryptamine Receptor 6

HTR6 Gene — 5-Hydroxytryptamine Receptor 6

<div class="infobox infobox-gene">
<h3>HTR6</h3>
<table>
<tr><th>Gene Symbol</th><td>HTR6</td></tr>
<tr><th>Full Name</th><td>5-Hydroxytryptamine Receptor 6</td></tr>
<tr><th>Chromosome</th><td>1p35.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[3362](https://www.ncbi.nlm.nih.gov/gene/3362)</td></tr>
<tr><th>OMIM</th><td>[604111](https://www.omim.org/entry/604111)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000158708](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158708)</td></tr>
<tr><th>UniProt ID</th><td>[P50406](https://www.uniprot.org/uniprot/P50406)</td></tr>
<tr><th>Protein Class</th><td>G protein-coupled receptor (GPCR)</td></tr>
<tr><th>Protein Size</th><td>440 amino acids (~46 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), Schizophrenia, Parkinson's Disease, Epilepsy</td></tr>
<tr><th>Expression</th><td>CNS (brain), primarily cortex and hippocampus</td></tr>
</table>
</div>

Introduction

HTR6 Gene — 5-Hydroxytryptamine Receptor 6

<div class="infobox infobox-gene">
<h3>HTR6</h3>
<table>
<tr><th>Gene Symbol</th><td>HTR6</td></tr>
<tr><th>Full Name</th><td>5-Hydroxytryptamine Receptor 6</td></tr>
<tr><th>Chromosome</th><td>1p35.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[3362](https://www.ncbi.nlm.nih.gov/gene/3362)</td></tr>
<tr><th>OMIM</th><td>[604111](https://www.omim.org/entry/604111)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000158708](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158708)</td></tr>
<tr><th>UniProt ID</th><td>[P50406](https://www.uniprot.org/uniprot/P50406)</td></tr>
<tr><th>Protein Class</th><td>G protein-coupled receptor (GPCR)</td></tr>
<tr><th>Protein Size</th><td>440 amino acids (~46 kDa)</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), Schizophrenia, Parkinson's Disease, Epilepsy</td></tr>
<tr><th>Expression</th><td>CNS (brain), primarily cortex and hippocampus</td></tr>
</table>
</div>

Introduction

The HTR6 gene (5-Hydroxytryptamine Receptor 6) encodes the 5-HT6 receptor, a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The 5-HT6 receptor has attracted significant interest as a therapeutic target for cognitive disorders, particularly Alzheimer's disease and schizophrenia, due to its role in modulating neurotransmitter release and neuronal signaling in brain regions critical for learning and memory [@woolley2004][@holenz2005].

The 5-HT6 receptor was first cloned in 1993 and represents one of the more recently identified serotonin receptor subtypes. Like all serotonin receptors, it belongs to the GPCR superfamily, characterized by seven transmembrane domains that signal through Gs proteins to stimulate adenylate cyclase activity. This signaling cascade ultimately leads to increased cAMP levels and activation of downstream effectors including protein kinase A (PKA) and the cAMP response element-binding protein (CREB).

The receptor's brain distribution is largely restricted to the central nervous system, with highest expression in brain regions associated with learning and memory, including the hippocampus and cerebral cortex. This localization, combined with its signaling properties, makes the 5-HT6 receptor an attractive target for cognitive enhancement strategies [@meneses2007][@ramirez2013].

Gene Structure and Protein

The HTR6 gene is located on chromosome 1p35.3 and encodes a 440-amino acid protein. Like other serotonin receptors, 5-HT6 contains seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus. The receptor couples preferentially to Gs proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels.

Expression Pattern

5-HT6 receptors show highest expression in:

• [Hippocampus](/brain-regions/hippocampus) - CA1, CA2, CA3 regions and dentate gyrus
• Cerebral [cortex](/brain-regions/cortex) - layers II-IV
• Basal ganglia - striatum
• Olfactory tubercle
• Hypothalamus

Molecular Signaling Pathways

Primary Signaling Cascade

Secondary Signaling Pathways

• MAPK/ERK pathway - cAMP can activate Rap1 → B-Raf → MEK → ERK
• PI3K/Akt pathway - Cross-talk with neurotrophic signaling
• Calcium mobilization - Indirect effects on calcium signaling through PKA

Disease Associations

Alzheimer's Disease

The 5-HT6 receptor has emerged as a promising target for cognitive enhancement in AD [@garciaalloza2011][@geldenhuys2019][@maheredwards2015]:

The failed clinical trials of idalopirdine and intepirdine in 2016-2018 highlighted the challenges of translating preclinical findings to human cognitive benefits. However, research continues on alternative approaches including combination therapies and biased agonists.

Parkinson's Disease

5-HT6 receptors are implicated in both motor and non-motor symptoms of PD [@dayer2018]:

• Modulation of dopaminergic and serotonergic pathways
• Potential for improving cognitive dysfunction in PD
• Interaction with levodopa therapy
• Possible role in dyskinesia development

Schizophrenia

• Cognitive symptoms: 5-HT6 modulators may improve cognitive deficits [@codony2011]
• Augmentation: Potential as augmentation to antipsychotic drugs
• Dopamine interaction: Modulates dopaminergic neurotransmission in prefrontal cortex

Other Neurological Disorders

• Epilepsy: Altered expression in epileptic tissue
• Depression/Anxiety: Anxiolytic effects of 5-HT6 antagonists [slattery2017]
• Obesity: 5-HT6 antagonists reduce food intake [@hume2013]
• Sleep disorders: 5-HT6 antagonists affect sleep architecture [morairty2013]
• Neurogenesis: 5-HT6 signaling influences hippocampal neurogenesis [fernandez2019]

Therapeutic Targeting

Drug Development

Multiple 5-HT6 ligands have been developed:

| Drug | Type | Development Status | Notes |
|------|------|-------------------|-------|
| Idalopirdine | Antagonist | Phase III (completed) | Failed to meet endpoints |
| Intepirdine | Antagonist | Phase III (completed) | Failed to meet endpoints |
| SAM-760 | Antagonist | Phase II | Cognitive enhancement |
| PRX-07034 | Antagonist | Phase I/II | Cognitive enhancement |

Challenges

• [Blood-brain barrier](/entities/blood-brain-barrier) penetration - Critical for CNS drugs
• Subtype selectivity - Avoiding off-target effects
• Efficacy - Translation from animal models to humans

Animal Models

• HTR6 knockout mice - Show altered learning and memory
• Transgenic models - Overexpression studies
• Pharmacological models - Use of selective agonists/antagonists

Key Publications

Brain Atlas Resources

• [Allen Human Brain Atlas - HTR6](https://human.brain-map.org/microarray/search/show?search_term=HTR6)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/)

References

See Also

• [Serotonin Receptors](/entities/serotonin-receptors)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Cognitive Enhancement](/therapeutics/cognitive-enhancement)
• [GPCR Signaling](/mechanisms/gpcr-signaling)

External Links

• [NCBI Gene: HTR6](https://www.ncbi.nlm.nih.gov/gene/3362)
• [UniProt: HTR6](https://www.uniprot.org/uniprot/P50406)
• [Ensembl: HTR6](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158708)
• [OMIM: 604111](https://www.omim.org/entry/604111)
• [Ensembl ENSG00000158708](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000158708)